We can’t show the full text here under this license. Use the link below to read it at the source.
Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2
Immune response and protection from an mRNA vaccine using a virus-like spike protein against COVID-19
AI simplified
Abstract
In animal studies, mRNA- vaccines generated stronger neutralizing antibody responses across multiple variants compared to conventional mRNA vaccines.
- The novel platform encodes virus-like particle antigens that mimic the structure of the native virus.
- In non-human primates, elevated antibody levels from mRNA-VLP vaccines persisted for at least six months.
- An mRNA-VLP vaccine encoding the Omicron spike showed improved performance over traditional mRNA vaccines in mice.
- In hamsters, low doses of the mRNA-VLP vaccine provided complete protection, similar to high doses of native spike mRNA vaccines.
- These findings indicate that the mRNA-VLP platform may enhance vaccine efficacy and coverage against changing SARS-CoV-2 variants.
AI simplified
Key numbers
236 vs. 68
nAb GMT Increase
nAb GMTs for Delta vs. mRNA-native Delta at 196 days post-vaccination.
2 µg
Complete Protection
2 µg of bivalent protected hamsters from weight loss post-infection.
6 months
nAb Durability
Duration of elevated nAb levels in non-human primates post-vaccination.